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ABSTRACT
The human lung cancer database (HLungDB) is a
database with the integration of the lung cancer-
related genes, proteins and miRNAs together with
the corresponding clinical information. The main
purpose of this platform is to establish a network
of lung cancer-related molecules and to facilitate
the mechanistic study of lung carcinogenesis. The
entries describing the relationships between
molecules and human lung cancer in the current
release were extracted manually from literatures.
Currently, we have collected 2585 genes and 212
miRNA with the experimental evidences involved in
the different stages of lung carcinogenesis through
text mining. Furthermore, we have incorporated the
results from analysis of transcription factor-binding
motifs, the promoters and the SNP sites for each
gene. Since epigenetic alterations also play an
important role in lung carcinogenesis, genes with
epigenetic regulation were also included. We hope
HLungDB will enrich our knowledge about lung
cancer biology and eventually lead to the develop-
ment of novel therapeutic strategies. HLungDB can
be freely accessed at http://www.megabionet
.org/bio/hlung.
INTRODUCTION
Lung cancer, one of the most common causes of cancer-
related death in both men and women, is responsible for
1.3 million deaths worldwide every year. Lung cancer
can be roughly divided into two groups according to
pathology: non-small cell lung cancer (NSCLC) (80.4%)
and small cell lung cancer (16.8%) (1). Many factors
potentially contribute to lung cancer formation, e.g.
tobacco smoke, ionizing radiation and viral infection.
However, the mechanisms involved in lung carcinogenesis
remain largely unknown.
Similar to many other cancers, lung cancer is initiated
by activation of oncogenes or inactivation of tumor sup-
pressor genes (2). Previous studies have revealed the
various causes of lung cancer at the genomic level.
Mutations in the K-ras proto-oncogene are responsible
for 10–30% of lung adenocarcinomas (3,4). The epidermal
growth factor receptor (EGFR) regulates cell prolifera-
tion, apoptosis, angiogenesis and tumor invasion (3).
Oncogenic mutations and ampliﬁcation of EGFR are
common in non-small cell lung cancer and thus provide
the basis for treatment with EGFR inhibitors. In contrast,
Her2/neu oncogenic mutation is less frequently observed
(3). Other oncogenes involved include c-MET, NKX2-1,
PIK3CA and BRAF (3). Inactivation of tumor suppressor
genes plays important role in lung carcinogenesis. The p53
tumor suppressor gene, located on chromosome 17p, is
aﬀected in 60–75% of lung cancer including both
NSCLC and SCLC while Rb is more likely inactivated
in SCLC (5). P16 is also frequently inactivated through
the methylation of its promoter region at genomic DNA
level. Another important tumor suppressor gene is LKB1,
whose loss-of-function mutation/deletion is observed
in 30% lung adenocarcinomas and 20% of squamous
cell carcinomas (6,7). Genetic polymorphisms are also
indicated to be involved in lung carcinogenesis, e.g.
interleukin-1 (8), cytochrome P450 (9), apoptosis
promoters such as caspase-8 (10) and DNA repair mole-
cules such as XRCC1 (11). People with these
polymorphisms are susceptible to lung cancer
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suggest that the MDM2 309G allele is a low-penetrant
risk factor for lung cancer development in Asian popula-
tion (12).
Although lung cancer research data have accumulated
dramatically during the past several years, to our knowl-
edge, there is no database speciﬁcally focusing on lung
cancer molecular biology yet available. OMIM contains
information on all known Mendelian disorders and
focuses on the relationship between phenotype and
genotype (13). MethyCancer is developed to study the
interplay of DNA methylation, gene expression and
cancer. It contains both highly integrated data of DNA
methylation, cancer-related genes, mutation and cancer
information from public resources, and the CpG Island
(CGI) clones derived from the large-scale sequencing
projects (14). MiR2Disease aims at providing a compre-
hensive resource of microRNA misregulation in various
human diseases (15). EGFR Mutation Database has a
convenient compilation of somatic EGFR mutations in
NSCLC and associated epidemiological and methodolog-
ical data, including response to the tyrosine kinase
inhibitors Geﬁtinib and Erlotinib (16). These databases
focus on cancer pathogenesis from diﬀerent angles with
a little touch of lung cancer. Thus, it is beneﬁcial to estab-
lish a lung cancer-related database or platform involving
genes/proteins/miRNAs.
High-throughput techniques applied in the lung cancer
research have generated a mass of data and provided
important resources for us to potentially explore the
molecular mechanisms and identify lung cancer-related
molecules. The integration of information generated by
small-scale studies and using high-throughput technology
could provide a unique resource to facilitate the systematic
study of the lung carcinogenesis process. To this end, we
collected lung cancer-related molecules and other detailed
information for database construction through text
mining in combination with bioinformatics analysis. This
repository and maintenance system specially designed for
lung cancer information can no doubt facilitate future
lung cancer investigations.
Overall, HLungDB enables the exploration of relevant
information for human lung cancer-related molecules
from multiple angles, making it a unique resource for
human lung cancer and will serve as a useful platform
for those interested in lung cancer biology.
DATA COLLECTION AND CONTENT
As aforementioned, initial entries describing the relation-
ship between genes and human lung cancer are collected
manually. The gene–lung cancer relationship documented
in the current release were collected through searching the
PubMed database with a list of keywords, such as ‘lung
cancer gene’, ‘pulmonary cancer gene’, ‘pulmonary
adenocarcinoma gene’, etc. After we obtained the litera-
ture with the keywords above, we read through and inter-
preted each paper by collecting the important
information, including the type of gene alteration, the
clinical correlation and/or signiﬁcance of the gene
alternation with lung cancer, the lung cancer subtype,
the potential mechanism of gene regulation and the exper-
imental methods involved.
Each entry in the database contains detailed informa-
tion on a lung cancer–gene relationship, including a basic
description of the gene, the expression pattern of gene (up-
or down-regulated) in the lung cancer patient, the exper-
imentally validated regulatory information (transcription
factors, their binding motif and the promoter) and
protein–protein interaction (PPI) network etc.
Gene expression proﬁling data for lung cancer patient
samples were also retrieved from GEO. The diﬀerentially
expressed genes were selected if the change between lung
cancer samples and normal control is larger than 2-fold.
To make the results more reliable, we only selected those
genes diﬀerentially expressed from at least three patients
in a dataset and displayed them on our web site.
In the current release of HLungDB, 2585 genes were
selected for their relationships with lung carcinogenesis.
A total of 271 lung cancer samples from six expression
proﬁling datasets were analyzed to get the gene expression
pattern (17–22). For the lung cancer-related SNPs, we
searched PubMed with key words, namely ‘SNP’ and
‘lung cancer’. Then, we collected the SNPs proven to be
correlated with lung cancer from those returned papers. In
total, 424 SNPs, no matter whether they could be mapped
to a gene or not, were added into the database.
Additionally, 360 transcription factors with 1160 binding
motifs and 253 lung cancer-related genes with detailed
epigenetic information were also placed into the database.
Accumulating evidence has indicated that miRNAs play
an important role in lung cancer pathology. Previous
experiments, both with high-throughput and small-scale
methods, have identiﬁed many miRNAs diﬀerentially
expressed in lung cancer and/or conﬁrmed to be related
to lung cancer. Hence, miRNA data are an important
resource for lung cancer research. Therefore, we selected
lung cancer-related miRNAs with experimental informa-
tion from the literature. For those miRNAs with identiﬁed
targets, the targets along with the experiment methods
used are also provided in the platform. Currently, there
are 212 lung cancer-related miRNAs included in the
HLungDB.
Next, we built the HLungDB database by integrating
the data we collected with information from other
resources (Figure 1), which makes our database a one-
stop and knowledgeable platform for the lung cancer
research community.
DATA ACCESS
HLungDB provides a search engine to query detailed
information on each gene–lung cancer relationship docu-
mented in the database. Query keywords, including gene/
protein symbol or its synonym, are all allowed. The infor-
mation ﬂow is roughly described in Figure 2.
After submission of the symbol or the alias of a gene,
gene centered information will be displayed in a new page,
including symbol, alias, description, protein–protein
interactions, expression alterations based on the
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Figure 2. The ﬂowchart of query in the HLungDB database.
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has been conﬁrmed to be related to lung cancer in our
database. To see more details about how the gene is
related to lung cancer, the user can click on the gene
symbol link and a new page will appear to display
evidence of the genes relationship to lung cancer.
‘Clinical Signiﬁcance’ indicates the eﬀect of the gene alter-
ation on the lung cancer in the point of clinical view that is
collected from the literature; ‘Function’ describes the
gene’s role in lung cancer extracted from the published
papers; ‘Gene Regulation’ presents the regulatory rela-
tionship of the gene with other genes, while ‘Expression
Alteration’ shows the analysis results of lung cancer
related microarray datasets, in which the user can see
how many patients show gene upregulation and/or
downregulation.
The PPI link leads to a new page that shows the proteins
interacting with the query protein, the ‘Show PPI
Network’ link will display the selected protein–protein
interaction network based on experimental evidence
mostly from the HPRD system (23). In the PPI network
section, user-friendly interfaces have made all the features
of HLungDB PPI easily accessible and also provide direct
view for the user to explore the relationship among the
proteins.
The ‘Regulatory Information’ links the user to the
names of the transcription factors conﬁrmed to regulate
the gene. ‘See Details’ links the user to a new page
that displays the binding site motifs of those transcrip-
tion factors with the supporting PubMed ID. The
‘Show Promoter of Gene’ link will display the promoter
sequence(s) of the selected gene. A gene with an unknown
transcription factor will only show its promoter
sequence(s).
Alternatively, the user can query our system with the
protein symbol, and a new summary page will provide a
brief description of the protein, the PPI, the links to other
related resources and the PPI network. Users can navigate
each item in detail by clicking the related links.
Users can also check whether a miRNA is related to
lung cancer with the miRNA symbol. The results page
will display the manually collected details for the related
miRNA, including the disease type the miRNA is related
to, the alterations in expression of the miRNA, the mech-
anism of the miRNA in lung cancer, the experiment
methods used to conﬁrm the mechanism, the targets of
the miRNA if any with PubMed ID and the description
of the miRNA involved in lung cancer.
HLungDB provides two ways to view all lung
cancer-related genes. The ﬁrst approach is to query the
database via visualized chromosome browser through
‘Chromosome’ listed on the ﬁrst page. The user then
clicks ‘Chromosome’ on the top of this page, and a chro-
mosome map will return. In the Chromosome page, the
user can view lung cancer-related genes by Chromosome
ID. With the second approach, ‘Browse’ on the ﬁrst page
of HLungDB allows users to see all the genes conﬁrmed to
be related to lung cancer. The genes in this list are sorted
by alphabetical order. Using these two approaches, users
can easily retrieve all genes that are related to lung cancer.
Another way to view lung cancer-related genes is
provided in the pathway view. On the pathway list, users
can check those lung cancer genes by clicking on the
pathway name and view the network about this pathway
through the ‘Pathway Network’ entrance. User can also
click on the marginal node on the network to expand the
network. For more detailed usage of the network, users
can read the annotation on the pathway network page.
Users can view lung cancer-related information in
our database through browsing SNP, transcription
factor and methylation lists. The ‘SNP View’ provides
the user with lung cancer-related SNP obtained
from PubMed by searching ‘SNP’ and ‘lung cancer’. The
‘TransFactor View’ presents transcription factors related
to lung cancer with other detailed information. The
‘Methylation View’ displays genes with epigenetic
alterations observed in lung cancer.
In addition, convenient links are provided to other
databases. HLungDB has been developed with crosslink
to other relevant external resources. It includes the
National Center for Biotechnology Information, a
repository for published gene information, and PubMed,
US National Library of Medicine, that includes over
18 million citations from MEDLINE and other life
science journals. HPRD, HUGO, IPI, EBI and KEGG
are also linked to HLungDB.
DISCUSSION
In order to provide a central resource for biologists in
the lung cancer research community, we developed
HLungDB, a database system aimed at providing a com-
prehensive resource of gene information and their
relationships to lung cancer.
The goal of the lung cancer database project was to
construct a large-scale platform for lung cancer that
would contribute to basic research and clinical research
in the future. In the past 2 years, large amounts of data
have been collected for this project. Information on lung
cancer data was obtained from the PubMed and GEO
databases. Genes, miRNAs, gene promoters, transcription
factors, transcription factor-binding sites and the SNPs
related to lung cancer have been collected and integrated
into this system. Clinical information related to gene
expression proﬁle data was also extracted from GEO.
We have systematically extracted information from
published lung cancer-related studies. The database
currently contains 2585 full-text entries describing lung
cancer and genes. They have been integrated in such a
way that investigators can rapidly query whether a gene
or protein is found in human lung cancer, and other
detailed lung cancer-related information about this gene.
User-friendly query interfaces have made all the features
of HLungDB easily accessible.
HLungDB provides a comprehensive resource for
human lung cancer research. We believe that HLungDB
will be particularly interesting to the life science commu-
nity and will greatly facilitate cancer biologists’ mission of
unraveling the pathogenesis of lung cancer.
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We are working to increase the quality and quantity of
data and to supply additional database function. We plan
to adopt two strategies to achieve these goals. First, text-
mining tools will be adopted to improve our data collec-
tion. We will use text-mining tools to help us prescreen
PubMed abstracts regularly that potentially describe the
lung cancer–gene relationships. Second, since many
proteins in the signaling transduction pathways are
involved in the lung cancer development and progression,
our next step is to identify those signal transduction
pathways that have signiﬁcant changes and display their
components with identiﬁed alteration in lung cancer in a
network view. At the same time, we will also collect the
downstream genes for each altered signaling pathway in
lung cancer and further characterize the relationship
between them to ultimately fulﬁll the goal of identifying
new potentially relevant lung cancer genes and new
mechanisms.
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